There are 3161 resources available
1389P - Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease
Presenter: Siddhartha Goutam
Session: Poster session 06
1390P - Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumour
Presenter: Inès Duparc
Session: Poster session 06
1393TiP - A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC)
Presenter: Nicolas Girard
Session: Poster session 06
1394TiP - KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation
Presenter: Marina Garassino
Session: Poster session 06
1395TiP - A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)
Presenter: Antonio Passaro
Session: Poster session 06
1397TiP - Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy
Presenter: Stephen Liu
Session: Poster session 06
Resources:
Abstract
1398TiP - Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
Presenter: Solange Peters
Session: Poster session 06